This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Genetics, Other  • Cardiovascular Intervention  • Thrombolysis  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2006;296:1453-1454.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

While most individuals may not notice any personal benefit resulting from the well-celebrated completion of the sequencing of the human genome in 2003, researchers and physicians say that the information gleaned has changed care for many patients with various conditions and will increasingly do so in the years ahead. And one area the human genome information is expected to revolutionize is pharmacogenomics, the science of how genes affect the way individuals respond to drugs.

As pharmacogenomics is a relatively new field and no evidence-based guidelines have been set, the National Academy of Clinical Biochemistry, the professional academy for scientists in the field of clinical biochemistry, has assembled a committee of about a dozen experts from academia, industry, and the government to establish laboratory management practice guidelines for the application of pharmacogenetics testing in health care (http://www.aacc.org/AACC/members/nacb/LMPG/OnlineGuide/DraftGuidelines/Pharmacogentics/). The proposed guidelines, which are currently open for comment, . . . [Full Text of this Article]

PHARMACOGENOMICS MODELS